Sec. 1001. BEAU BIDEN CANCER MOONSHOT AND NIH INNOVATION PROJECTS
1,465 words·~7 min read·
/statute-compilations/comps-13005/sec-1001A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
## SEC. 1001 BEAU BIDEN CANCER MOONSHOT AND NIH INNOVATION PROJECTS ###
(a)In general The Director of the National Institutes of Health (referred to in this section as the “Director of NIH”) shall use any funds appropriated pursuant to the authorization of appropriations in subsection (b)(3) to carry out the National Institutes of Health innovation projects described in subsection (b)(4) (referred to in this section as the “NIH Innovation Projects”). ###
(b)National Institutes of Health Innovation Account ####
(1)Establishment of nih innovation account There is established in the Treasury an account, to be known as the “NIH Innovation Account” (referred to in this subsection as the “Account”), for purposes of carrying out the NIH Innovation Projects described in paragraph (4). ####
(2)Transfer of direct spending savings #####
(A)In general The following amounts shall be transferred to the Account from the general fund of the Treasury: ######
(i)For fiscal year 2017, $352,000,000. ######
(ii)For fiscal year 2018, $496,000,000. ######
(iii)For fiscal year 2019, $711,000,000. ######
(iv)For fiscal year 2020, $492,000,000. ######
(v)For fiscal year 2021, $404,000,000. ######
(vi)For fiscal year 2022, $496,000,000. ######
(vii)For fiscal year 2023, $1,085,000,000. ######
(viii)For fiscal year 2024, $407,000,000. ######
(ix)For fiscal year 2025, $127,000,000. ######
(x)For fiscal year 2026, $226,000,000. #####
(B)Amounts deposited Any amounts transferred under subparagraph
(A)shall remain unavailable in the Account until such amounts are appropriated pursuant to paragraph (3). ####
(3)Appropriations #####
(A)Authorization of Appropriations For each of the fiscal years 2017 through 2026, there is authorized to be appropriated from the Account to the Director of NIH, for the purpose of carrying out the NIH Innovation Projects, an amount not to exceed the total amount transferred to the Account under paragraph (2)(A), to remain available until expended. #####
(B)Offsetting future appropriations For any of fiscal years 2017 through 2026, for any discretionary appropriation under the heading “NIH Innovation Account” provided to the Director of NIH pursuant to the authorization of appropriations under subparagraph
(A)for the purpose of carrying out the NIH Innovation Projects, the total amount of such appropriations for the applicable fiscal year (not to exceed the total amount remaining in the Account) shall be subtracted from the estimate of discretionary budget authority and the resulting outlays for any estimate under the Congressional Budget and Impoundment Control Act of 1974 or the Balanced Budget and Emergency Deficit Control Act of 1985, and the amount transferred to the Account shall be reduced by the same amount. ####
(4)NIH innovation projects NIH Innovation Projects authorized to be funded under this section shall consist of the following and, of the total amounts authorized to be appropriated under paragraph (3), there are authorized to be appropriated to each such project a total amount not to exceed the following, over the period of fiscal years 2017 through 2026: #####
(A)For the Precision Medicine Initiative, including for the advancement of a cohort of individuals to support the goals of the Precision Medicine Initiative, not to exceed a total of $1,455,000,000, as follows: ######
(i)For fiscal year 2017, $40,000,000. ######
(ii)For fiscal year 2018, $100,000,000. ######
(iii)For fiscal year 2019, $186,000,000. ######
(iv)For fiscal year 2020, $149,000,000. ######
(v)For fiscal year 2021, $109,000,000. ######
(vi)For fiscal year 2022, $150,000,000. ######
(vii)For fiscal year 2023, $419,000,000. ######
(viii)For fiscal year 2024, $235,000,000. ######
(ix)For fiscal year 2025, $36,000,000. ######
(x)For fiscal year 2026, $31,000,000. #####
(B)For the Brain Research through Advancing Innovative Neurotechnologies Initiative (known as the “BRAIN Initiative”), not to exceed a total of $1,511,000,000, as follows: ######
(i)For fiscal year 2017, $10,000,000. ######
(ii)For fiscal year 2018, $86,000,000. ######
(iii)For fiscal year 2019, $115,000,000. ######
(iv)For fiscal year 2020, $140,000,000. ######
(v)For fiscal year 2021, $100,000,000. ######
(vi)For fiscal year 2022, $152,000,000. ######
(vii)For fiscal year 2023, $450,000,000. ######
(viii)For fiscal year 2024, $172,000,000. ######
(ix)For fiscal year 2025, $91,000,000. ######
(x)For fiscal year 2026, $195,000,000. #####
(C)To support cancer research, such as the development of cancer vaccines, the development of more sensitive diagnostic tests for cancer, immunotherapy and the development of combination therapies, and research that has the potential to transform the scientific field, that has inherently higher risk, and that seeks to address major challenges related to cancer, not to exceed a total of $1,800,000,000, as follows: ######
(i)For fiscal year 2017, $300,000,000. ######
(ii)For fiscal year 2018, $300,000,000. ######
(iii)For fiscal year 2019, $400,000,000. ######
(iv)For fiscal year 2020, $195,000,000. ######
(v)For fiscal year 2021, $195,000,000. ######
(vi)For fiscal year 2022, $194,000,000. ######
(vii)For fiscal year 2023, $216,000,000. #####
(D)For the National Institutes of Health, in coordination with the Food and Drug Administration, to award grants and contracts for clinical research to further the field of regenerative medicine using adult stem cells, including autologous stem cells, for which grants and contracts shall be contingent upon the recipient making available non-Federal contributions toward the costs of such research in an amount not less than $1 for each $1 of Federal funds provided in the award, not to exceed a total of $30,000,000, as follows: ######
(i)For fiscal year 2017, $2,000,000. ######
(ii)For each of fiscal years 2018 and 2019, $10,000,000. ######
(iii)For fiscal year 2020, $8,000,000. ######
(iv)For each of fiscal years 2021 through 2026, $0. ###
(c)Accountability and Oversight ####
(1)Work plan #####
(A)In general Not later than 180 days after the date of enactment of this Act, the Director of NIH shall submit to the Committee on Health, Education, Labor, and Pensions and the Committee on Appropriations of the Senate and the Committee on Energy and Commerce and the Committee on Appropriations of the House of Representatives, a work plan including the proposed allocation of funds authorized to be appropriated pursuant to subsection (b)(3) for each of fiscal years 2017 through 2026 for the NIH Innovation Projects and the contents described in subparagraph (B). #####
(B)Contents The work plan submitted under subparagraph
(A)shall include— ######
(i)recommendations from the Advisory Committee described in subparagraph (C); ######
(ii)the amount of money to be obligated or expended in each fiscal year for each NIH Innovation Project; ######
(iii)a description and justification of each such project; and ######
(iv)a description of how each such project supports the strategic research priorities identified in the NIH Strategic Plan under subsection
(m)of section 402 of the Public Health Service Act (42 U.S.C. 282), as added by section 2031. #####
(C)Recommendations Prior to submitting the work plan under this paragraph, the Director of NIH shall seek recommendations from the Advisory Committee to the Director of NIH appointed under section 222 of the Public Health Service Act (42 U.S.C. 217a) on— ######
(i)the allocations of funds appropriated pursuant to the authorization of appropriations under subsection (b)(3) for each of fiscal years 2017 through 2026; and ######
(ii)on the contents of the proposed work plan. ####
(2)Reports #####
(A)Annual reports Not later than October 1 of each of fiscal years 2018 through 2027, the Director of NIH shall submit to the Committee on Health, Education, Labor, and Pensions and the Committee on Appropriations of the Senate and the Committee on Energy and Commerce and the Committee on Appropriations of the House of Representatives, a report including— ######
(i)the amount of money obligated or expended in the prior fiscal year for each NIH Innovation Project; ######
(ii)a description of any such project using funds provided pursuant to the authorization of appropriations under subsection (b)(3); and ######
(iii)whether such projects are advancing the strategic research priorities identified in the NIH Strategic Plan under subsection
(m)of section 402 of the Public Health Service Act (42 U.S.C. 282), as added by section 2031. #####
(B)Additional reports At the request of the Committee on Health, Education, Labor, and Pensions or the Committee on Appropriations of the Senate, or the Committee on Energy and Commerce or the Committee on Appropriations of the House of Representatives, the Director of NIH shall provide an update in the form of testimony and any additional reports to the respective congressional committee regarding the allocation of funding under this section or the description of the NIH Innovation Projects. ###
(d)Limitations Notwithstanding any transfer authority authorized by this Act or any appropriations Act, any funds made available pursuant to the authorization of appropriations under subsection (b)(3) may not be used for any purpose other than a NIH Innovation Project. ###
(e)Sunset This section shall expire on September 30, 2026.
Connectionstraces to 2
Traces to 2 documents
Citation graph
cites case law
Cites 2Cited by 0 across 0 sources